Table 2.

Demographic information for all the dogs that completed the Dog Aging Project Rapamycin Intervention Phase I Trial

Group	Breed	Sex	Age (years)	Weight (kg)
Placebo	Standard poodle	FS	9.7	21
Placebo	Mixed breed	MN	10	44
Placebo	Mixed breed	MN	6.6	31
Placebo	Mixed breed	FS	7.2	25
Placebo	Labrador retriever	FS	6.8	26
Placebo	Mixed breed	MN	8.3	27
Placebo	Great Dane	FS	10.4	37
Placebo	Mixed breed	MN	7.5	33
Low	Mixed breed	MN	8.8	34
Low	Mixed breed	FS	12.7	34
Low	Golden retriever	FS	12	31
Low	English bulldog	MN	7.2	34
Low	Mixed breed	FS	10.8	31
High	Golden retriever	FS	9.2	31
High	Mixed breed	FS	8	36
High	Wheaten terrier	MN	8.3	22
High	Labrador retriever	MI	7.9	34
High	Chow	FS	9.6	23
High	Mixed breed	FS	11.5	22
High	Doberman	FS	6.8	24
High	Labrador retriever	MN	11.1	38
High	Labrador retriever	FS	8	36
High	Mixed breed	MN	6.8	31
Higha	Mixed breed	MN	11.1	29

The breed indicates owner-reported information. Age is owner-reported age at the time of the first exam, verified by age indicated on veterinary records. The weight is the measured weight at the first exam

Sex is indicated as follows, verified at initial exam. FS female spayed, FI female intact, MN male neutered, MI male intact

^aA dog that was randomized to the high rapamycin group and completed the entire 10-week study, but it was discovered upon reviewing the dosing log that the owners had mistakenly provided the dog with 0.025 mg/kg rapamycin three times each week. This dog was removed from analysis of the high rapamycin group, but was included in analysis of the pooled (low and high dose) rapamycin-treated dogs